[go: up one dir, main page]

AU2001294920A1 - Chrono delivery formulations and method of use thereof - Google Patents

Chrono delivery formulations and method of use thereof

Info

Publication number
AU2001294920A1
AU2001294920A1 AU2001294920A AU9492001A AU2001294920A1 AU 2001294920 A1 AU2001294920 A1 AU 2001294920A1 AU 2001294920 A AU2001294920 A AU 2001294920A AU 9492001 A AU9492001 A AU 9492001A AU 2001294920 A1 AU2001294920 A1 AU 2001294920A1
Authority
AU
Australia
Prior art keywords
delivery formulations
chrono
chrono delivery
formulations
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294920A
Inventor
Given Not
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001294920A1 publication Critical patent/AU2001294920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001294920A 2000-10-03 2001-10-02 Chrono delivery formulations and method of use thereof Abandoned AU2001294920A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/678,335 2000-10-03
US09/678,335 US6620439B1 (en) 2000-10-03 2000-10-03 Chrono delivery formulations and method of use thereof
PCT/US2001/030627 WO2002028376A2 (en) 2000-10-03 2001-10-02 Chrono delivery formulations and method of use thereof

Publications (1)

Publication Number Publication Date
AU2001294920A1 true AU2001294920A1 (en) 2002-04-15

Family

ID=24722368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294920A Abandoned AU2001294920A1 (en) 2000-10-03 2001-10-02 Chrono delivery formulations and method of use thereof

Country Status (5)

Country Link
US (2) US6620439B1 (en)
EP (1) EP1322297A2 (en)
JP (1) JP2004528270A (en)
AU (1) AU2001294920A1 (en)
WO (1) WO2002028376A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627842T3 (en) * 2002-02-21 2017-07-31 Valeant Pharmaceuticals Luxembourg S.À.R.L. Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20040096496A1 (en) * 2002-08-16 2004-05-20 Orchid Chemicals & Pharmaceuticals Limited Sustained release pharmaceutical composition of a cephalosporin antibiotic
PL1631251T3 (en) 2003-04-24 2011-12-30 Jagotec Ag Delayed release tablet with defined core geometry
EP1615626B1 (en) * 2003-04-24 2009-10-14 Jagotec Ag Tablet with coloured core
EP1479383B1 (en) * 2003-05-20 2006-10-04 Ethypharm Oral sustained release pharmaceutical composition
US7410978B2 (en) * 2003-11-04 2008-08-12 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
WO2005077331A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
DE102004043863A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with local and time-controlled drug release in the gastrointestinal tract
US20080318311A1 (en) 2004-11-02 2008-12-25 Gangagen Life Sciences Inc. Encapsulated Bacteriophage Formulation
AU2006235565A1 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
AU2006261788B2 (en) 2005-06-27 2012-05-31 Valeant International Bermuda Modified-release formulations of a bupropion salt
DK1915137T3 (en) * 2005-08-10 2013-11-04 Add Advanced Drug Delivery Technologies Ltd Controlled-release oral preparation
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
PT2049123E (en) 2006-08-03 2013-03-06 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
NZ592616A (en) 2008-11-11 2013-04-26 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
CA2750611A1 (en) * 2009-01-22 2010-08-12 Abbott Healthcare Private Limited Chronotherapeutic pharmaceutical composition
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
ES2924478T3 (en) * 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulation of pharmaceutical tablets for the veterinary medical sector, method of production and use thereof
HUE054186T2 (en) 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Preserved liquid aqueous pharmaceutical composition containing etherified cyclodextrin derivatives
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN114129541B (en) * 2022-01-05 2023-05-30 南通联亚药业股份有限公司 Diltiazem hydrochloride sustained-release capsule and preparation method and application thereof
CN117618379A (en) * 2023-12-27 2024-03-01 杭州泓友医药科技有限公司 Diclofenac sodium double-release enteric capsule and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043877A1 (en) 1980-07-14 1982-01-20 Russell Richard Ferrers Wakelin Method and apparatus for displacing fluids by means of an oscillating blade
IE56999B1 (en) 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US5336504A (en) 1987-10-16 1994-08-09 Elan Corporation, Plc Diltiazem formulations and methods of treatment
JP2558396B2 (en) * 1990-06-28 1996-11-27 田辺製薬株式会社 Controlled release formulation
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof

Also Published As

Publication number Publication date
JP2004528270A (en) 2004-09-16
US6620439B1 (en) 2003-09-16
WO2002028376A2 (en) 2002-04-11
EP1322297A2 (en) 2003-07-02
US20030165565A1 (en) 2003-09-04
US6926909B2 (en) 2005-08-09
WO2002028376A3 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AU2001294920A1 (en) Chrono delivery formulations and method of use thereof
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2001286940A1 (en) Drug delivering prostheses and methods of use
AU2001233526A1 (en) Stent delivery system and method of use
AU2001281344A1 (en) Angulated stent delivery system and method of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
IL160853A0 (en) Nicotine containing formulations and use thereof
AU2002361060A1 (en) Use of apple core extracts in cosmetic or pharmaceutical compositions
AU2001222986A1 (en) Dehydroascorbic acid formulations and uses thereof
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU5800399A (en) Polish composition and method of use
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU8235601A (en) Dispenser and method of use
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
WO2001091700A8 (en) Composition and method for enhancing elasticity of tissue
IL211958A0 (en) Lactone formulations and method of use
AU2002221273A1 (en) Delayed and sustained release formulations and method of use thereof
AU2002251801A1 (en) Composition containing hedychium extract and use thereof
AU2962400A (en) Cleaner composition and method of use thereof
AU2001287198A1 (en) Dental restorative compositions and method of use thereof
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2002363800A1 (en) Therapeutic agent composition and method of use